Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE) has been given a consensus recommendation of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $4.10.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Fate Therapeutics in a research note on Thursday, January 22nd.

Fate Therapeutics Price Performance

FATE stock opened at $1.10 on Monday. The firm has a market cap of $127.89 million, a price-to-earnings ratio of -0.96 and a beta of 2.18. Fate Therapeutics has a 1-year low of $0.66 and a 1-year high of $1.94. The firm has a fifty day moving average price of $1.24 and a two-hundred day moving average price of $1.18.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.27). Fate Therapeutics had a negative net margin of 2,051.08% and a negative return on equity of 55.02%. The company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $1.20 million. As a group, analysts expect that Fate Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Fate Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC bought a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $28,000. Commonwealth Equity Services LLC bought a new position in Fate Therapeutics during the 4th quarter worth $26,000. Russell Investments Group Ltd. increased its position in Fate Therapeutics by 73.1% in the third quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 12,114 shares during the period. Corient Private Wealth LLC acquired a new stake in Fate Therapeutics in the fourth quarter worth $29,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Fate Therapeutics in the fourth quarter worth $35,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.